SITE-SPECIFIC GENE THERAPY FOR MYOCARDIAL ANGIOGENESIS

心肌血管生成的位点特异性基因治疗

• 批准号: 2744838
• 负责人: WEILIAM CHEN
• 金额: $ 21.84万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-27 至 2002-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2744838
• 关键词: DNA; angiogenesis; bioengineering /biomedical engineering; biomaterial development /preparation; biotechnology; cardiac myocytes; copolymer; gene expression; gene therapy; laboratory rat; myocardial ischemia /hypoxia; myocardium; nanotechnology; nonsurgical revascularization; technology /technique development; transfection; transfection /expression vector; vascular endothelial growth factors

DESCRIPTION (Adapted from Applicant's Abstract): The research and development of genetic delivery for treatment of ischemic heart disease is the focus of many investigations. However current techniques of gene delivery are inefficient and very limited in scope. The objective of the proposed studies is to develop a biodegradable polymer-based DNA delivery system for sustained release of vascular endothelial growth factor (VEGF) to promote revascularization in ischemic myocardium. Specifically, the applicant proposes to: encapsulate DNA in small nanometer diameter particles with a poly-lactic-polyglycolic acid co-polymer, assess the in vitro delivery mechanism of nanoparticles using beta -galactosidase as a model reporter gene, and then finally to evaluate the efficacy of VEGF gene transfer in a rat cardiac injection model. These experiments may help establish the feasibility of using this delivery system for gene therapy.

描述（根据申请人的摘要改编）：研发 治疗缺血性心脏病的基因分娩是 许多调查。但是当前基因输送技术是 效率低下且范围非常有限。拟议的研究的目的是 开发基于可生物降解的聚合物DNA输送系统以持续 释放血管内皮生长因子（VEGF）以促进 缺血性心肌的血运重建。具体而言，申请人提出了 TO：将DNA封装在小纳米直径颗粒中 多乳酸聚糖酸共聚物，评估体外递送 使用β-半乳糖苷酶作为模型报告基因的纳米颗粒机理 然后最终评估VEGF基因转移在大鼠中的疗效 心脏注射模型。这些实验可能有助于确定可行性 使用该输送系统进行基因治疗。